COVID-19 Vaccines, Therapies Would Get Billion-Dollar Manufacturing Platform Under House Bill
Executive Summary
House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.
You may also be interested in...
Advanced Manufacturing Centers Of Excellence Measure Finally Clears US Congress
Nearly four years after introduction and a half-dozen legislative attempts, proposal to establish academic centers of excellence – hoped to help usher in a renaissance in US pharmaceutical manufacturing – secures passage in omnibus spending bill. New law also supports emerging technologies, building on the FDA’s Critical Path Initiative.
Supply Chain Resilience Measures Included In Senate Coronavirus Bill
Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.
Drug Shortage Legislation Gains Support As Coronavirus Threatens US Supplies
Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.